Characteristics of patients with sudden (n = 4) or gradual onset (n = 19) of blastic transformation
Characteristics . | SBT . | Gradual BP . |
|---|---|---|
| No. patients | 4 | 19 |
| Best CG response, no. patients | ||
| CR | 4 | 0 |
| PR | 0 | 2 |
| Minor | 0 | 2 |
| CHR only | 0 | 11 |
| No CHR | 0 | 8 |
| Best molecular response, no. patients | ||
| Undetectable | 1 | 0* |
| < 0.05 | 1 | 0 |
| ≥ 0.05 | 2 | 5 |
| Median time to best CG response, mo (range) | 45 (3-6) | 9.3 (3-22) |
| Median time from diagnosis to imatinib, mo (range) | 2.3 (0.1-34.9) | 73.2 (0.9-171.5) |
| Time from start of imatinib to BP, mo (range) | 19.5 (12-25) | 7.3 (1.9-54.3) |
| Morphology, no. patients | ||
| Lymphoid | 2 | 8 |
| Myeloid | 2 | 8 |
| Unknown | 0 | 3 |
| CE at start of imatinib, no. patients | 0 | 5 |
| CE at BP, no. patients | 4 | 3† |
| Prior therapy, no. patients | ||
| IFN-α | 1 | 16 |
| None | 3 | 3 |
| Sokal risk group, no. patients low/intermediate/high | 3/1/0 | 10/4/5 |
| No. dead | 0 | 15 |
Characteristics . | SBT . | Gradual BP . |
|---|---|---|
| No. patients | 4 | 19 |
| Best CG response, no. patients | ||
| CR | 4 | 0 |
| PR | 0 | 2 |
| Minor | 0 | 2 |
| CHR only | 0 | 11 |
| No CHR | 0 | 8 |
| Best molecular response, no. patients | ||
| Undetectable | 1 | 0* |
| < 0.05 | 1 | 0 |
| ≥ 0.05 | 2 | 5 |
| Median time to best CG response, mo (range) | 45 (3-6) | 9.3 (3-22) |
| Median time from diagnosis to imatinib, mo (range) | 2.3 (0.1-34.9) | 73.2 (0.9-171.5) |
| Time from start of imatinib to BP, mo (range) | 19.5 (12-25) | 7.3 (1.9-54.3) |
| Morphology, no. patients | ||
| Lymphoid | 2 | 8 |
| Myeloid | 2 | 8 |
| Unknown | 0 | 3 |
| CE at start of imatinib, no. patients | 0 | 5 |
| CE at BP, no. patients | 4 | 3† |
| Prior therapy, no. patients | ||
| IFN-α | 1 | 16 |
| None | 3 | 3 |
| Sokal risk group, no. patients low/intermediate/high | 3/1/0 | 10/4/5 |
| No. dead | 0 | 15 |